Toru Wakamatsu

Dr. Toru Wakamatsu

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2022 in Frontiers in Oncology
Verified
Journal Article
Open access
TWToru Wakamatsu
Toru Wakamatsu
HOHisataka Ogawa
Hisataka Ogawa
KYKeiichi Yoshida
Keiichi Yoshida
YMYukiko Matsuoka
Yukiko Matsuoka
KSKazuko Shizuma
Kazuko Shizuma
STSatoshi Takenaka
Satoshi Takenaka
Background: Although biological resources are essential for basic and preclinical research in the oncological field, those of sarcoma are not sufficient for rapid development of the treatment. So far, some sarcoma cell lines have been established, however, the success rate was low and the established sarcoma types were frequently biased. Therefore, an efficient culture method is needed to determine the various types of sarcomas. Organoid culture is a 3-dimentional culture method that enables the recapitulation of the tumor microenvironment and the success rate reported is higher than the 2-dimentional culture. The purpose of this study was to report our newly established organoids from human epithelioid sarcoma using the air-liquid interface organoid culture method.Methods: We treated 2 patients with epithelioid sarcoma in our institute. The remaining sarcoma specimens after surgical resection were embedded in collagen type 1 gels according to the air-liquid interface organoid culture method. After serial passages, we xenografted the organoids to NOD-scid IL2Rgnull (NSG) mice. Using the developed tumors, we performed histological and genomic analyses to compare the similarities and differences with the original epithelioid sarcoma from the patient.Results: Organoids from the epithelioid sarcoma could be serially cultured and maintained in collagen type 1 gels for more than 3 passages. Developed orthotopic tumor xenografts were detected in the NSG mice. After the process was repeated severally, the patient derived organoid lines from the epithelioid sarcoma were established. The established organoids showed loss of integrase interactor 1 expression with polymerase chain reaction and immunohistochemical analyses. The xenografted organoids of the epithelioid sarcoma had histologically similar phenotypes with the original tumor and genetically resembled it to some degree.Conclusions: The present study demonstrated 2 novel established organoid models of epithelioid sarcoma, and our organoid models could be used to investigate the molecular pathogenesis and develop a novel treatment.

7 August 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
YIYoshinori Imura
Yoshinori Imura
HYHirohiko Yasui
Hirohiko Yasui
HOHidetatsu Outani
Hidetatsu Outani
TWToru Wakamatsu
Toru Wakamatsu
KHKenichiro Hamada
Kenichiro Hamada
NNNorifumi Naka
Norifumi Naka
Epithelioid sarcoma (EpS) is a high-grade malignant soft-tissue sarcoma characterized by local recurrences and distant metastases. Effective treatments for EpS have not been established and thus novel therapeutic approaches against EpS are urgently required. mTOR inhibitors exert antitumor effects on several malignancies but AKT reactivation by mTOR inhibition attenuates the antitumor effects of mTOR inhibitors. This reactivation is receptor tyrosine kinase (RTK)-dependent due to a release of negative feedback inhibition. We found that c-MET was the most highly activated RTK in two human EpS cell lines, Asra-EPS and VAESBJ. Here we investigated the functional and therapeutic relevance of mTOR and/or c-MET signaling pathways in EpS both in vitro and in vivo. We first examined the effects of an mTOR inhibitor, RAD001 (everolimus), on cell proliferation, cell cycle, AKT/mTOR signaling, and xenograft tumor growth in EpS cell lines. Next, we determined whether RAD001-induced AKT reactivation was blocked by silencing of c-MET or treatment with a selective c-MET inhibitor, INC280. Finally, we evaluated the antitumor effects of RAD001 combined with INC280 on EpS cell lines compared with either single agent or control in vitro and in vivo. Constitutive AKT phosphorylation was observed in Asra-EPS and VAESBJ cells. RAD001 suppressed EpS cell growth by inducing cell cycle arrest but enhanced AKT phosphorylation, which resulted in intrinsic resistance to mTOR inhibitors. In both EpS cell lines, RAD001-induced AKT phosphorylation was dependent on c-MET signaling. INC280 inhibited phosphorylation of c-MET and its downstream molecules, and decreased RAD001-induced phosphorylation of both AKT and ERK in EpS. Compared with a single agent or control, the combination of RAD001 and INC280 exerted superior antitumor effects on the growth of EpS cell lines in vitro and in vivo. Targeting of mTOR and c-MET signaling pathways significantly abrogates the growth of EpS in preclinical models and may be a promising therapeutic approach for patients with EpS.

11 December 2019 in Cancer
Verified
Journal Article
Closed access
PDF file
HKHiroshi Kobayashi
Hiroshi Kobayashi
Shintaro IwataShintaro Iwata
Shintaro Iwata
TWToru Wakamatsu
Toru Wakamatsu
KHKeiko Hayakawa
Keiko Hayakawa
TYTsukasa Yonemoto
Tsukasa Yonemoto
STSakae Tanaka
Sakae Tanaka

19 June 2014 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HOHidetatsu Outani
Hidetatsu Outani
TTTakaaki Tanaka
Takaaki Tanaka
TWToru Wakamatsu
Toru Wakamatsu
YIYoshinori Imura
Yoshinori Imura
KHKenichiro Hamada
Kenichiro Hamada
NNNorifumi Naka
Norifumi Naka
Clear cell sarcoma (CCS) is a therapeutically unresolved, aggressive, soft tissue sarcoma (STS) that predominantly affects young adults. This sarcoma is defined by t(12;22)(q13;q12) translocation, which leads to the fusion of Ewing sarcoma gene (EWS) to activating transcription factor 1 (ATF1) gene, producing a chimeric EWS-ATF1 fusion gene. We established a novel CCS cell line called Hewga-CCS and developed an orthotopic tumor xenograft model to enable comprehensive bench-side investigation for intensive basic and preclinical research in CCS with a paucity of experimental cell lines.

22 February 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
YXYuchen Xie
Yuchen Xie
MSMerve Sahin
Merve Sahin
TWToru Wakamatsu
Toru Wakamatsu
AIAkane Inoue-Yamauchi
Akane Inoue-Yamauchi
WZWanming Zhao
Wanming Zhao
ECEmily H. Cheng
Emily H. Cheng
SETD2 , a H3K36 trimethyltransferase, is the most frequently mutated epigenetic modifier in lung adenocarcinoma, with a mutation frequency of approximately 9%. However, how SETD2 loss of function promotes tumorigenesis remains unclear. Using conditional Setd2 -KO mice, we demonstrated that Setd2 deficiency accelerated the initiation of Kras G12D -driven lung tumorigenesis, increased tumor burden, and significantly reduced mouse survival. An integrated chromatin accessibility and transcriptome analysis revealed a potentially novel tumor suppressor model of SETD2 in which SETD2 loss activates intronic enhancers to drive oncogenic transcriptional output, including the KRAS transcriptional signature and PRC2-repressed targets, through regulation of chromatin accessibility and histone chaperone recruitment. Importantly, SETD2 loss sensitized KRAS-mutant lung cancer to inhibition of histone chaperones, the FACT complex, or transcriptional elongation both in vitro and in vivo. Overall, our studies not only provide insight into how SETD2 loss shapes the epigenetic and transcriptional landscape to promote tumorigenesis, but they also identify potential therapeutic strategies for SETD2 mutant cancers.

4 April 2020 in Journal of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
HOHidetatsu Otani
Hidetatsu Otani
STSatoshi Takenaka
Satoshi Takenaka
KHKenichiro Hamada
Kenichiro Hamada
YIYoshinori Imura
Yoshinori Imura
SKShigeki Kakunaga
Shigeki Kakunaga
NANobuhito Araki
Nobuhito Araki